Enfortumab Vedotin Approved for Bladder Cancer in India

In a historic development for oncology care, Astellas Pharma has launched enfortumab vedotin in India in combination with pembrolizumab. This groundbreaking regimen offers a powerful first-line treatment option for adult patients facing unresectable or metastatic urothelial cancer. Consequently, clinicians now have a highly effective alternative to traditional platinum-containing chemotherapy, the historical standard of care. Indeed, this approval represents a major therapeutic advancement for those pursuing clinical oncology.

Improving Survival Rates with Enfortumab Vedotin in India

The approval rests on the robust results from the Phase 3 EV-302 clinical trial. Specifically, the trial compared the novel combination against standard platinum-based chemotherapy. The results demonstrated that the combination achieved a median overall survival of 31.5 months. On the other hand, patients on standard chemotherapy experienced a median overall survival of only 16.1 months. Furthermore, the combination therapy demonstrated a 53% reduction in the risk of death. Therefore, these findings highlight a significant milestone in bladder cancer management.

Clinical Implications and Safety Profile

This therapy delivers a dual mechanism by combining an antibody-drug conjugate with an immunotherapy agent. Indeed, the combination successfully targets Nectin-4 expressing cancer cells while boosting the patient’s immune response. However, oncologists must carefully monitor patients for potential adverse events. Common side effects include skin reactions, peripheral neuropathy, and hyperglycemia. Therefore, proactive supportive care remains essential during treatment cycles for those interested in expanding their expertise through oncology speciality courses.

Frequently Asked Questions

Q1: What is the newly approved indication for enfortumab vedotin in India?

The CDSCO approved this combination for the first-line treatment of adult patients with unresectable or metastatic urothelial cancer who are eligible for platinum-containing chemotherapy.

Q2: What clinical trial supported this CDSCO approval?

The Phase 3 EV-302 clinical trial supported this regulatory clearance by demonstrating a significant overall survival benefit.

References

1. PADCEVTM (enfortumab vedotin) in Combination with pembrolizumab is Now Availablefor the first-line treatment of adult patients with unresectable or metastaticurothelial cancer who are eligible for platinum-containing chemotherapy in India – ETHealthworld
2. Central Drugs Standard Control Organisation (CDSCO). Recommendations of the SEC (Oncology) meeting. Government of India.
3. U.S. Food and Drug Administration (FDA). FDA approves enfortumab vedotin-ejfv with pembrolizumab for locally advanced or metastatic urothelial cancer.

Disclaimer: This article was automatically generated from publicly available sources and is provided for informational and educational purposes only. OC Academy does not exercise editorial control or claim authorship over this content. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider and refer to current local and national clinical guidelines.